Sinopsis
New and exciting data presented each day during the conference and address the potential impact on current clinical practice.
Episodios
-
![William J. Sandborn, MD, FACG: Positioning anti-IL-12 and anti-IL-23 inhibitors]()
William J. Sandborn, MD, FACG: Positioning anti-IL-12 and anti-IL-23 inhibitors
21/12/2018 Duración: 18minWebcast: Advances in IBD 2018 - Clinical Track
-
![Brian G. Feagan, MD, FACG: Positioning inhibitors of lymphocyte trafficking]()
Brian G. Feagan, MD, FACG: Positioning inhibitors of lymphocyte trafficking
21/12/2018 Duración: 20minWebcast: Advances in IBD 2018 - Clinical Track
-
![Corey J. Langer, MD, Helen J. Ross, MD, Charu Aggarwal, MD, Lyudmila Bazhenova, MD: Case-based Panel Discussion on EGFR-Mutant NSCLC]()
Corey J. Langer, MD, Helen J. Ross, MD, Charu Aggarwal, MD, Lyudmila Bazhenova, MD: Case-based Panel Discussion on EGFR-Mutant NSCLC
31/10/2018 Duración: 32minWebcast: Therapeutic Challenges in EGFR-Mutant NSCLC: Addressing Treatment Choices and Resistance
-
![Lyudmila Bazhenova, MD: Understanding, preventing, and delaying EGFR resistance in the era of Osimertinib]()
Lyudmila Bazhenova, MD: Understanding, preventing, and delaying EGFR resistance in the era of Osimertinib
31/10/2018 Duración: 20minWebcast: Therapeutic Challenges in EGFR-Mutant NSCLC: Addressing Treatment Choices and Resistance
-
![Charu Aggarwal, MD: Targeted treatment with EGFR TKIs: Front line options]()
Charu Aggarwal, MD: Targeted treatment with EGFR TKIs: Front line options
31/10/2018 Duración: 20minWebcast: Therapeutic Challenges in EGFR-Mutant NSCLC: Addressing Treatment Choices and Resistance
-
![Helen J. Ross, MD: Heterogeneity of NSCLC and precipitating oncogenic driver mutations]()
Helen J. Ross, MD: Heterogeneity of NSCLC and precipitating oncogenic driver mutations
31/10/2018 Duración: 16minWebcast: Therapeutic Challenges in EGFR-Mutant NSCLC: Addressing Treatment Choices and Resistance
-
![Morton Coleman, MD and John P. Leonard, MD: Highlights in Lymphoma]()
Morton Coleman, MD and John P. Leonard, MD: Highlights in Lymphoma
31/10/2018 Duración: 22minKey Insights: Lymphoma and Myeloma 2018: An International Congress on Hematologic Malignancies
-
![Morton Coleman, MD and Richard R. Furman, MD: Highlights in Chronic Lymphocytic Leukemia]()
Morton Coleman, MD and Richard R. Furman, MD: Highlights in Chronic Lymphocytic Leukemia
31/10/2018 Duración: 22minKey Insights: Lymphoma and Myeloma 2018: An International Congress on Hematologic Malignancies
-
![Morton Coleman, MD and Ruben Niesvizky, MD: Highlights in Multiple Myeloma]()
Morton Coleman, MD and Ruben Niesvizky, MD: Highlights in Multiple Myeloma
31/10/2018 Duración: 20minKey Insights: Lymphoma and Myeloma 2018: An International Congress on Hematologic Malignancies
-
![Peter Martin, MD: How I approach early relapsing follicular lymphoma]()
Peter Martin, MD: How I approach early relapsing follicular lymphoma
31/10/2018 Duración: 18minWebcast: Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity and Impact of an Emerging Therapeutic Class
-
![John P. Leonard, MD: New data on upfront and maintenance therapy in follicular lymphoma]()
John P. Leonard, MD: New data on upfront and maintenance therapy in follicular lymphoma
31/10/2018 Duración: 24minWebcast: Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity and Impact of an Emerging Therapeutic Class
-
![Anas Younes, MD: New antibodies and antibody-drug conjugates for B-cell lymphoma]()
Anas Younes, MD: New antibodies and antibody-drug conjugates for B-cell lymphoma
31/10/2018 Duración: 16minWebcast: Surviving and Thriving with B-Cell Malignancies: Surveying an Ever-Evolving Landscape
-
![Nancy L. Bartlett, MD: Kinase inhibitors for follicular and marginal zone lymphoma: Opportunities and challenges]()
Nancy L. Bartlett, MD: Kinase inhibitors for follicular and marginal zone lymphoma: Opportunities and challenges
31/10/2018 Duración: 19minWebcast: Surviving and Thriving with B-Cell Malignancies: Surveying an Ever-Evolving Landscape
-
![Rita M. Jakubowski, NP: CAR T-cell in lymphoma]()
Rita M. Jakubowski, NP: CAR T-cell in lymphoma
31/10/2018 Duración: 51minWebcast: CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis
-
![Caron A. Jacobson, MD: Auto-transplant vs CAR-T: How should we sequence the therapy who should receive therapy?]()
Caron A. Jacobson, MD: Auto-transplant vs CAR-T: How should we sequence the therapy; who should receive therapy?
31/10/2018 Duración: 16minWebcast: CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis
-
![Caron A. Jacobson, MD: What does the future hold with CAR-T cell therapy?]()
Caron A. Jacobson, MD: What does the future hold with CAR-T cell therapy?
31/10/2018 Duración: 22minWebcast: CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis
-
![Peter Hillmen, MB, ChB, PhD: The sequencing of novel agents: Does it matter?]()
Peter Hillmen, MB, ChB, PhD: The sequencing of novel agents: Does it matter?
31/10/2018 Duración: 22minWebcast: Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice
-
![Kanti Rai, MD: Changing treatment paradigm for CLL over the years]()
Kanti Rai, MD: Changing treatment paradigm for CLL over the years
31/10/2018 Duración: 23minWebcast: Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice
-
![Neil E. Kay, MD: Treatment options for the young patient with deletion 17p: Do they need a different approach?]()
Neil E. Kay, MD: Treatment options for the young patient with deletion 17p: Do they need a different approach?
31/10/2018 Duración: 19minWebcast: Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice
-
![Richard R. Furman, MD: Update on venetoclax: How low can you go (MRD)?]()
Richard R. Furman, MD: Update on venetoclax: How low can you go (MRD)?
31/10/2018 Duración: 21minWebcast: Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice
